Ken Peh
★    

Malaysia,
2013-05-21 21:24
(4766 d 09:41 ago)

Posting: # 10612
Views: 5,637
 

 Tmax, ke and t1/2 in fully replicate design of HVD [General Sta­tis­tics]

Dear All,

When we run a fully replicate design for highly variable drug, may I know how elimination rate constant (ke) and elimination half-life (t1/2) are analyzed statistically ? Same as for AUC ??

What about Tmax ? As Tmax is analyzed statistically using non-parametric test for 2-way crossover design (2x2), I presumed this parameter should also be analyzed the same way for fully replicate design (2x4). The only difference is taking the average of Tmax of test and reference product.

Appreciate if could kindly comment on the above.

Thank you.

Regards,
Ken
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2013-05-22 22:54
(4765 d 08:11 ago)

@ Ken Peh
Posting: # 10621
Views: 4,589
 

 No stats

Hi Ken!

❝ […] how elimination rate constant (ke) and elimination half-life (t1/2) are analyzed statistically ? Same as for AUC ??


Nobody requires a comparison. Elimination is drug-specific (i.e., does not depend on the formulation). Just report the means ± SD (geometric – or harmonic, if you want to split hairs).

❝ What about Tmax ? As Tmax is analyzed statistically using non-parametric test for 2-way crossover design (2x2), I presumed this parameter should also be analyzed the same way for fully replicate design (2x4). The only difference is taking the average of Tmax of test and reference product.


Wait until the draft will be finalized: No statistical comparison required any more. ;-)

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
Ken Peh
★    

Malaysia,
2013-05-23 13:44
(4764 d 17:21 ago)

@ Helmut
Posting: # 10627
Views: 4,506
 

 No stats

Dear Helmut,

Thank you very much for your input.

❝ Wait until the draft will be finalized: No statistical comparison required any more.


May I know which guideline ? FDA ?

Regards,
Ken
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2013-05-23 14:03
(4764 d 17:02 ago)

@ Ken Peh
Posting: # 10628
Views: 4,565
 

 No stats

Hi Ken!

❝ ❝ Wait until the draft will be finalized: No statistical comparison any more.

❝ May I know which guideline ?


The ASEAN draft GL Section 3.1.8 states “A statistical evaluation of tmax is not required.”

❝ FDA ?


tmax is not required for ages. FDA wants partial AUC truncated at the median tmax of the reference as metric of early exposure.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,570 registered users;
252 visitors (0 registered, 252 guests [including 36 identified bots]).
Forum time: 07:06 CEST (Europe/Vienna)

The epistemological value of probability theory is based on the fact
that chance phenomena, considered collectively and on a grand scale,
create non-random regularity.    Andrey Kolmogorov

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5